A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib. Dai S, Liu XQ, Wu Q, Du CM, et al. Lung Cancer 2023;175:121-124.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dai S, Liu XQ, Wu Q, Du CM, et al. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib. Lung Cancer 2023;175:121-124.
PMID: 36495785